vs
Arcellx, Inc.（ACLX）与AIM ImmunoTech Inc.（AIM）财务数据对比。点击上方公司名可切换其他公司
Arcellx, Inc.的季度营收约是AIM ImmunoTech Inc.的78.8倍（$1.7M vs $21.0K）。Arcellx, Inc.净利率更高（-3513.4% vs -19881.0%，领先16367.5%）。AIM ImmunoTech Inc.同比增速更快（-53.3% vs -89.2%）。过去两年AIM ImmunoTech Inc.的营收复合增速更高（-27.5% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
ACLX vs AIM — 直观对比
营收规模更大
ACLX
是对方的78.8倍
$21.0K
营收增速更快
AIM
高出35.8%
-89.2%
净利率更高
ACLX
高出16367.5%
-19881.0%
两年增速更快
AIM
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $21.0K |
| 净利润 | $-58.1M | $-4.2M |
| 毛利率 | — | — |
| 营业利润率 | -3850.2% | -14057.1% |
| 净利率 | -3513.4% | -19881.0% |
| 营收同比 | -89.2% | -53.3% |
| 净利润同比 | -23.4% | 30.0% |
| 每股收益（稀释后） | $-1.01 | $-6.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXAIM
| Q4 25 | $1.7M | $21.0K | ||
| Q3 25 | $4.9M | $26.0K | ||
| Q2 25 | $7.6M | $25.0K | ||
| Q1 25 | $8.1M | $16.0K | ||
| Q4 24 | $15.3M | $45.0K | ||
| Q3 24 | $26.0M | $35.0K | ||
| Q2 24 | $27.4M | $50.0K | ||
| Q1 24 | $39.3M | $40.0K |
净利润ACLXAIM
| Q4 25 | $-58.1M | $-4.2M | ||
| Q3 25 | $-55.8M | $-3.3M | ||
| Q2 25 | $-52.8M | $-2.8M | ||
| Q1 25 | $-62.3M | $-3.7M | ||
| Q4 24 | $-47.1M | $-6.0M | ||
| Q3 24 | $-25.9M | $-3.7M | ||
| Q2 24 | $-27.2M | $-1.8M | ||
| Q1 24 | $-7.2M | $-5.8M |
营业利润率ACLXAIM
| Q4 25 | -3850.2% | -14057.1% | ||
| Q3 25 | -1248.3% | -9411.5% | ||
| Q2 25 | -777.4% | -10584.0% | ||
| Q1 25 | -847.6% | -22618.8% | ||
| Q4 24 | -348.2% | -13011.1% | ||
| Q3 24 | -129.1% | -12825.7% | ||
| Q2 24 | -127.8% | -7388.0% | ||
| Q1 24 | -40.3% | -14335.0% |
净利率ACLXAIM
| Q4 25 | -3513.4% | -19881.0% | ||
| Q3 25 | -1127.1% | -12630.8% | ||
| Q2 25 | -698.6% | -11176.0% | ||
| Q1 25 | -766.0% | -23156.3% | ||
| Q4 24 | -308.4% | -13260.0% | ||
| Q3 24 | -99.4% | -10571.4% | ||
| Q2 24 | -99.3% | -3672.0% | ||
| Q1 24 | -18.3% | -14542.5% |
每股收益（稀释后）ACLXAIM
| Q4 25 | $-1.01 | $-6.46 | ||
| Q3 25 | $-0.99 | $1.57 | ||
| Q2 25 | $-0.94 | $-3.68 | ||
| Q1 25 | $-1.13 | $-0.05 | ||
| Q4 24 | $-0.87 | $-21.80 | ||
| Q3 24 | $-0.48 | $-6.00 | ||
| Q2 24 | $-0.51 | $-3.00 | ||
| Q1 24 | $-0.14 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $3.0M |
| 总债务越低越好 | — | $4.5M |
| 股东权益账面价值 | $402.4M | $-9.8M |
| 总资产 | $604.0M | $5.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXAIM
| Q4 25 | $450.3M | $3.0M | ||
| Q3 25 | $461.4M | $2.4M | ||
| Q2 25 | $453.1M | $835.0K | ||
| Q1 25 | $543.3M | $2.2M | ||
| Q4 24 | $587.4M | $4.0M | ||
| Q3 24 | $574.3M | $7.2M | ||
| Q2 24 | $516.7M | $10.1M | ||
| Q1 24 | $573.9M | $10.9M |
总债务ACLXAIM
| Q4 25 | — | $4.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $3.3M |
股东权益ACLXAIM
| Q4 25 | $402.4M | $-9.8M | ||
| Q3 25 | $440.8M | $-6.1M | ||
| Q2 25 | $392.2M | $-6.5M | ||
| Q1 25 | $416.9M | $-3.9M | ||
| Q4 24 | $454.8M | $-1.3M | ||
| Q3 24 | $483.0M | $2.9M | ||
| Q2 24 | $487.2M | $6.1M | ||
| Q1 24 | $496.6M | $4.8M |
总资产ACLXAIM
| Q4 25 | $604.0M | $5.8M | ||
| Q3 25 | $655.9M | $5.5M | ||
| Q2 25 | $619.1M | $4.1M | ||
| Q1 25 | $648.1M | $6.2M | ||
| Q4 24 | $711.3M | $8.6M | ||
| Q3 24 | $764.9M | $13.6M | ||
| Q2 24 | $734.3M | $15.7M | ||
| Q1 24 | $779.7M | $16.2M |
负债/权益比ACLXAIM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $-2.0M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | — |
| 自由现金流率自由现金流/营收 | -3563.4% | — |
| 资本支出强度资本支出/营收 | 46.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | — |
8季度趋势，按日历期对齐
经营现金流ACLXAIM
| Q4 25 | $-58.2M | $-2.0M | ||
| Q3 25 | $-49.2M | $-5.1M | ||
| Q2 25 | $-39.7M | $-1.5M | ||
| Q1 25 | $-63.1M | $-2.4M | ||
| Q4 24 | $-46.0M | $-4.0M | ||
| Q3 24 | $30.7M | $-3.1M | ||
| Q2 24 | $-36.2M | $-3.0M | ||
| Q1 24 | $-31.9M | $-4.8M |
自由现金流ACLXAIM
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | — | ||
| Q1 24 | $-38.3M | — |
自由现金流率ACLXAIM
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | — | ||
| Q1 24 | -97.7% | — |
资本支出强度ACLXAIM
| Q4 25 | 46.2% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.4% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
